摘要
去甲基化药物(HMA)已被许多国家应用于骨髓增生异常综合征(MDS)及低骨髓原始细胞急性髓系白血病(AML)患者的治疗,体力状态差与基础疾病多的老年AML患者也能从去甲基化治疗中获益,但对去甲基化药物抵抗的患者预后不良,因此临床上急需预测对去甲基化治疗反应的可靠指标,本文对预测MDS及AML患者去甲基化治疗反应的生物学指标作一综述。
In many countries the hypomethylating agents(HMAs) are the major compounds to treat patients suffering from myelodysplastic syndrome(MDS) and acute myeloid leukemia(AML) with low bone marrow blast counts.The elderly AML patients with poor performance status and comorbidity also benefit from HMAs.Patients who resist to HMA have a poorer outcome as compared to sensitive patients.Therefore,the reliable markers for predicting response to HMAs are urgeatly needed in clinic.In this review,the biomarkers for predicting response of patients with MDS or AML to HMAs are summarized.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2015年第6期1769-1773,共5页
Journal of Experimental Hematology
